BioXcel Therapeutics
BTAI
88 hedge funds and large institutions have $118M invested in BioXcel Therapeutics in 2023 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 37 increasing their positions, 21 reducing their positions, and 21 closing their positions.
76% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 21
14% more call options, than puts
Call options by funds: $6.79M | Put options by funds: $5.96M
0.04% more ownership
Funds ownership: 3.75% → 3.79% (+0.04%)
8% less funds holding
Funds holding: 96 → 88 (-8)
38% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 21
64% less capital invested
Capital invested by funds: $325M → $118M (-$207M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$7.27M |
| 2 |
State Street
Boston,
Massachusetts
|
+$6.48M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$5.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.04M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$7.63M |
| 2 |
Two Sigma Investments
New York
|
-$4.07M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.73M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.69M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.48M |
BTAI Hedge Fund Activity: Q2 2023 in Review
88 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q2 2023, worth a combined $118M — down 64% from $325M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of BTAI and 13 opened new positions — a net loss of 8 holders — while 21 trimmed existing stakes and 37 added.
The largest buyer was Ameriprise, opening a new position worth an estimated $7.27M. The largest seller was Driehaus Capital Management, cutting an estimated $7.63M.
- 88 institutional investors held BioXcel Therapeutics (BTAI) as of Q2 2023, down from 96 in Q1 2023.
- Funds reported $118M of BioXcel Therapeutics stock for Q2 2023, down 64% quarter-over-quarter.
- 13 funds opened new BioXcel Therapeutics positions in Q2 2023 and 21 closed out, a net change of -8 holders.
- The largest BioXcel Therapeutics buyer in Q2 2023 was Ameriprise, an estimated $7.27M added.
- The largest BioXcel Therapeutics seller in Q2 2023 was Driehaus Capital Management, an estimated $7.63M sold.
Based on aggregated 13F filings for Q2 2023.